Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours
2006 · British Journal of Cancer · 173 citations
https://doi.org/10.1038/sj.bjc.6603171
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
17
Papers
391
Citations
6
h-index
5
i10-index
M. Cianfrocca is an academic researcher from Utah Cancer Specialists. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Advanced Breast Cancer Therapies & Cancer Treatment and Pharmacology. The author has an h-index of 6, co-authored 15 publications.
Click to start Chat